EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)

Yu Abe, Shiro Kubonishi, Masaki Ri, Masaki Iino iD, Kazutaka Sunami, Tomoki Ito, Masafumi Fukaya, Toshiyuki Kitano, Sho Ikeda iD, Shuichi Ota, Taiga Kuroi, Noriyoshi Iriyama und 7 weitere

Future Oncology · 2024

DOI: 10.2217/fon-2023-0834 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Future Oncology, 2024. Verfasst von Yu Abe und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, 1508935, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Oligopeptides, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The ARROW study demonstrated that once-weekly carfilzomib and dexamethasone (wKd) therapy significantly prolonged progression-free survival compared with twice-weekly carfilzomib and dexamethasone therapy in relapsed or refractory multiple myeloma patients.

Aim

To describe the treatment patterns, effectiveness and safety of wKd therapy in real-world settings in Japan.

Methods

We investigated data from the medical records of 126 Japanese patients with relapsed or refractory multiple myeloma.

Results

The overall response rate was 66.3%. The median progression-free survival was 9.5 months. The incidence of treatment-emergent adverse events of any grade and grade ≥3 were 45.8 and 20.8%, respectively.

Conclusion

There were no new or unexpected safety signals in this study. This study demonstrated the effectiveness and safety profiles of wKd therapy in Japan. Carfilzomib became available for daily clinical practice as a drug for cancer of bone marrow (multiple myeloma) that comes back or does not respond to previous drug (relapsed or refractory). This drug was approved in the USA in 2012, and in Japan in 2016. In this study, we looked at how once-weekly carfilzomib works and how safe it is in real-life situations in Japan. We screened 126 patients with relapsed or refractory multiple myeloma in Japan. The median age of the patients was 70 years, with 25% being over 75 years. This study also included some patients who were not in the best overall health, had a history of many treatments or had heart complications. In 66.3% of patients, the cancer had disappeared or the extent of the cancer had reduced after treatment. Side effects and serious side effects occurred in 45.8 and 14.2% of patients, respectively. The most common side effects were low levels of blood platelets (9.2%), high blood pressure (5.8%), loose or watery stools (5.0%), fever (5.0%), and low levels of red blood cells (4.2%). Heart disorders occurred in five patients. But all patients recovered or improved with treatment such as blood pressure lowering drugs and diuretics. These results showed that once-weekly carfilzomib works well and is safe in real-world settings in Japan. This information can help us think about how to pick the right patients and handle heart disease risks when using carfilzomib treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaOligopeptidesAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansMaleFemaleAgedMiddle AgedJapanAged, 80 and overDrug Administration ScheduleAdultProgression-Free SurvivalTreatment OutcomeNeoplasm Recurrence, Local

Stichwörter der Autor:innen

ARROW studyJapanesecarfilzomibreal-worldrelapsed or refractory multiple myeloma

Substanzen

carfilzomibOligopeptidesDexamethasone

Autor:innen und Institutionen

  • Department of Hematology, Japanese Red Cross Medical Center, Tokyo, 1508935, Japan.
  • Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, 6708540, Japan.
  • Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Aichi, 4678602, Japan.
  • Department of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, 4008506, Japan.
  • Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, 7011192, Japan.
  • Division of Hematology, First Department of Internal Medicine, Kansai Medical University Medical Center, Moriguchi, Osaka, 5708507, Japan.

ORCID-Profile: Masaki Iino, Sho Ikeda, Teruaki Katayama

Förderung

  • Ono Pharmaceutical

Zitieren

APA

Abe, Y., Kubonishi, S., Ri, M., Iino, M., Sunami, K., Ito, T., Fukaya, M., Kitano, T., Ikeda, S., Ota, S., Kuroi, T., Iriyama, N., Jo, T., Adachi, M., Akahane, D., Kai, T., Kohara, Y., Kadowaki, N., & Katayama, T. (2024). An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study). Future Oncology. https://doi.org/10.2217/fon-2023-0834

Vancouver

Abe Y, Kubonishi S, Ri M, Iino M, Sunami K, Ito T, et al. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study). Future Oncology. 2024. doi:10.2217/fon-2023-0834

BibTeX
@article{Abe2024,
  author = {Abe, Yu and Kubonishi, Shiro and Ri, Masaki and Iino, Masaki and Sunami, Kazutaka and Ito, Tomoki and Fukaya, Masafumi and Kitano, Toshiyuki and Ikeda, Sho and Ota, Shuichi and Kuroi, Taiga and Iriyama, Noriyoshi and Jo, Tatsuro and Adachi, Masaaki and Akahane, Daigo and Kai, Tatsuyuki and Kohara, Yoichi and Kadowaki, Norimitsu and Katayama, Teruaki},
  title = {An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2023-0834}
}
Kostenlos starten →